Human Longevity Inc..

What HLI actually is

Human Longevity Inc. is the institutional pioneer of the genome-plus-MRI executive health model — co-founded by J. Craig Venter and Peter Diamandis in 2013, well before the current longevity-clinic boom. The Health Nucleus, in San Diego, is its flagship and currently sole clinical site.

The 100+ programme — $8,000 — is a single comprehensive day of diagnostics. The programme name dates the marketing; the medical practice has been refined across a decade of patient data, which is the longest run in this directory.

What you get

Whole-body MRI on a research-grade magnet. Whole-genome sequencing — actual short-read whole-genome, not a SNP chip. 120+ biomarkers. DEXA, VO₂ max, cardiac CT calcium, cognitive battery. AI-augmented MRI reading with same-day radiologist sign-off; findings are flagged in hours rather than the days that most institutional radiology requires.

The genomics work, ten years in, sits at a depth few competitors match: variant-level annotation against curated longevity-relevant gene sets, clinical correlation rather than consumer-grade reporting, and an institutional dataset deep enough to do meaningful population-level comparison.

On the model

HLI is structured as a diagnostic clinic. The 100+ programme is the visit, the visit is the product, and follow-up coordination is a referral function rather than a treatment franchise. We have not seen the structural treatment-ladder pattern at HLI that we see at the membership concierge clinics; the long-term financial model is the diagnostic itself plus enterprise contracts on the genomics side.

This is the right structure for an editorially sound diagnostic practice and is the reason HLI ranks meaningfully ahead of clinics with comparable diagnostic depth but heavier in-house treatment programmes.

Where it falls short

Three honest caveats.

Single-location. If you are not in Southern California, this is a flight, accommodation, and a day. The visit is worth the trip; planning it as a destination day is the right framing.

Brand surface is muted. HLI does not market like Fountain Life and does not have Peter Attia’s editorial reach. The practice is quieter than the field around it; readers who haven’t gone looking for HLI may have heard about every other major US clinic first.

The genomic data, while the deepest in the field, has the same 2026-stage limitation everyone faces: variant-to-action mapping is sparser than the marketing across the category implies. HLI is honest about this; the deeper question is what your $8,000 finding actually changes about your protocol.

The verdict

For the US-based reader who wants a single decisive diagnostic day with the strongest genomics back-end currently available, HLI is the well-tenured choice. The price is comparable to YEARS Evolve in Berlin; the geography is the operative variable.

A clinic that has been refining the same diagnostic since 2013 is, in 2026, a quieter asset than a brand-new launch. We weight tenure.